Evidence map›Paper›PMID 41484808›Full record

ArticleBiomarker research2026

Single-cell RNA sequencing unveils enhanced antitumor immunity in colorectal cancer with PD-1 blockade and LINC00673 deletion.

Yifei Zhu, Yanxi Yao, Yaxian Wang, Zhibing Qiu, Dingpei Zhou, Huixia Huang, Keji Chen, Qingyang Sun, Jiayu Chen, Yuxue Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yifei Zhu *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yanxi Yao *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yaxian Wang *Department of Oncology, Shanghai Medical College Fudan University, Shanghai, 200032, China.
Zhibing Qiu *Department of Digestive Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Dingpei ZhouShanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, 200031, China.
Huixia HuangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Keji ChenDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Qingyang SunDepartment of Oncology, Shanghai Medical College Fudan University, Shanghai, 200032, China.
Jiayu ChenDepartment of Oncology, Shanghai Medical College Fudan University, Shanghai, 200032, China.
Yuxue LiDepartment of Oncology, Shanghai Medical College Fudan University, Shanghai, 200032, China.
Jianqiang TangDepartment of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. doc_tjq@hotmail.com.
Dawei LiDepartment of Oncology, Shanghai Medical College Fudan University, Shanghai, 200032, China. li_dawei@fudan.edu.cn.
Ping WeiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. weiping@fudan.edu.cn.

Funding

National Natural Science Foundation of China 82273240National Natural Science Foundation of China 82473078Shanghai"Science and Technology Innovation Action Plan" Outstanding Academic Leader Program 22XD1420500Shanghai Shuguang Program 21SG09
6 · The paper itself

Abstract

backgroundMost colorectal cancers are resistant to immune checkpoint inhibitors due to an immunosuppressive tumor microenvironment. LINC00673, previously classified as a long non-coding RNA, has been implicated in tumor progression, but its role in antitumor immunity remains poorly understood.

methodsWe used single-cell RNA sequencing, flow cytometry, and functional assays in Linc00673 knockout and wild-type mouse models treated with programmed death 1 (PD-1) blockade to dissect changes in immune landscape and tumor cell behavior.

resultsLinc00673 deletion enhanced the efficacy of PD-1 therapy, reducing tumor burden and prolonging survival. KO tumors showed increased infiltration of cytotoxic CD8⁺ T cells, reduced exhaustion, and improved antigen presentation. The tumor microenvironment shifted toward a pro-inflammatory state, with elevated dendritic cell function, reduced immunosuppressive macrophages, and improved T cell–tumor interactions. Linc00673 also promoted tumor cell migration and immune evasion independently of immune cells, suggesting dual tumor-intrinsic and -extrinsic roles.

conclusionsLINC00673 suppresses antitumor immunity and promotes tumor aggressiveness. Its deletion synergizes with PD-1 blockade, revealing a promising therapeutic target to overcome immune resistance in colorectal cancer.

Indexed as

Colorectal cancerImmunotherapyLINC00673Single-cell RNA sequencingTumor microenvironment

Identifiers

PMID41484808
PMCPMC12810015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.